Tracking early signs of infectious disease with Evosep One to improve patient outcomes
In this session, we explore how cutting-edge technology can detect the early signs of infectious disease with precision and speed. Early identification of disease markers can significantly enhance patient care by allowing for faster, more effective treatments.
Learn how Evosep One’s robustness, sensitivity, and efficiency are helping laboratories and clinicians stay ahead of disease progression, providing key insights that lead to better health outcomes.
Accurate and early detection of mycobacterial pathogens is critical for improving patient outcomes. We developed and validated multiple novel diagnostic methods. First, an immuno-affinity liquid chromatography–tandem mass spectrometry (ILM) assay that quantifies Mycobacterium tuberculosis CFP10 peptides and HIV-1 p24 in serum, showing high sensitivity and specificity in both adults and children. This method allows early detection of HIV and TB and monitors treatment responses effectively. The second approach involves an automated peptidomics pipeline that rapidly identifies mycobacterial species and subspecies from early growth cultures, including drug-resistant strains, significantly reducing diagnosis time compared to current clinical practices. These methods present significant advancements for managing the mycobacterial diseases.
Presenter: PhD. Tony Hu (Center for Cellular & Molecular Diagnostics, Tulane Cancer Center Translational Oncology Research Program Leader)
Presenter: Aaron Scott (Infection Medicine (BMC) – Faculty of Medicine, Lund University)
